Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Michael Bristow to Vasodilator Agents

This is a "connection" page, showing publications Michael Bristow has written about Vasodilator Agents.

 
Connection Strength
 
 
 
1.026
 
  1. Bristow MR. Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy? JACC Heart Fail. 2014 Dec; 2(6):558-60.
    View in: PubMed
    Score: 0.407
  2. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol. 1998 Dec; 21(12 Suppl 1):I3-13.
    View in: PubMed
    Score: 0.136
  3. Bristow MR, Larrabee P, M?ller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig. 1992; 70 Suppl 1:S105-13.
    View in: PubMed
    Score: 0.084
  4. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, M?ller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992; 19 Suppl 1:S68-80.
    View in: PubMed
    Score: 0.084
  5. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar; 88(3):223-9.
    View in: PubMed
    Score: 0.074
  6. MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
    View in: PubMed
    Score: 0.068
  7. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest. 1981 Aug; 45(2):157-68.
    View in: PubMed
    Score: 0.041
  8. Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail. 2001 Jun; 7(2):114-21.
    View in: PubMed
    Score: 0.040
  9. Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
    View in: PubMed
    Score: 0.040
  10. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
    View in: PubMed
    Score: 0.028
  11. Hershberger RE, Feldman AM, Bristow MR. A1-adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium. Circulation. 1991 Apr; 83(4):1343-51.
    View in: PubMed
    Score: 0.020
  12. Bristow M. Vasodilation in treatment of hypertension. N Engl J Med. 1970 May 07; 282(19):1102.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)